Following registration with the South African Health Products Regulatory Authority (SAHPRA), Dolutegravir (DTG) 10mg dispersible, scored tablets are now recommended as part of the standard first-line antiretroviral regimen for children(<:: 4 weeks to <10 years of age) in the weight band 3 - 20 kg. The benefits of OTG 10mg dispersible, scored tablets (pDTG) include increased clinical efficacy, better side effect profile, ease of administration and improved palatability. The pDTG tablets replaces Lopinavir/ritonavir and children should be switched to the DTG 50mg formulation after 20kg, unless there are challenges swallowing whole tablets.